Cargando…

Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer

PURPOSE: Previous retrospective studies reported that proton-pump inhibitors (PPIs) may decrease the efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) including gefitinib and erlotinib. Afatinib had a wider soluble pH range, with possible fewer inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Meng-Chin, Chung, Ying-Shan, Lin, Yu-Ching, Hung, Ming-Szu, Fang, Yu-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805747/ https://www.ncbi.nlm.nih.gov/pubmed/36597496 http://dx.doi.org/10.2147/OTT.S387165

Ejemplares similares

Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam
por: Vu, Thanh Ha, et al.
Publicado: (2021)

Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study
por: Fang, Yu-Hung, et al.
Publicado: (2019)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
por: Tsai, Ming-Ju, et al.
Publicado: (2023)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
por: Ho, Gwo-Fuang, et al.
Publicado: (2019)

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023)

Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
por: Kwok, Wang Chun, et al.
Publicado: (2022)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study
por: Chuang, Min-Chun, et al.
Publicado: (2021)

Transformation to small cell lung cancer after first-line afatinib treatment
por: Shiroyama, Takayuki, et al.
Publicado: (2018)

Long-Term Usage of Proton Pump Inhibitors Associated with Prognosis in Patients with Colorectal Cancer
por: Wu, Chin-Chia, et al.
Publicado: (2023)

Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy
por: Nishizawa, Toshihiro, et al.
Publicado: (2012)

Successful erlotinib rechallenge in an EGFR‐mutant metastatic non‐small cell lung cancer patient with afatinib‐induced drug rash with eosinophilia and systemic symptoms: A case report
por: Lin, Chung‐Fu, et al.
Publicado: (2021)

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
por: Liang, Sheng-Kai, et al.
Publicado: (2017)

Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Associated Clostridioides difficile Infection Among Patients with Lung Cancer
por: Chung, Ying-Shan, et al.
Publicado: (2022)

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies
por: Wu, Chieh-Chen, et al.
Publicado: (2023)

First reported case of afatinib‐associated toxic megacolon
por: Kwok, Wang Chun, et al.
Publicado: (2018)

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
por: Ricciuti, Biagio, et al.
Publicado: (2018)

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
por: Lu, Shun, et al.
Publicado: (2021)

Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study
por: Liang, Sheng-Kai, et al.
Publicado: (2018)

Voltage Dependence of Proton Pumping by Bacteriorhodopsin Mutants with Altered Lifetime of the M Intermediate
por: Geibel, Sven, et al.
Publicado: (2013)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure
por: Hsieh, Szu-Min, et al.
Publicado: (2009)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022)

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
por: Keller, Simone, et al.
Publicado: (2018)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2017)

Effect of proton pump inhibitors on mortality of cirrhotic patients with pneumonia
por: Hung, Tsung-Hsing, et al.
Publicado: (2019)

Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
por: Westerink, Lotte, et al.
Publicado: (2020)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib
por: Ruiz-Garcia, Ana, et al.
Publicado: (2020)

Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression
por: Cholin, Liza, et al.
Publicado: (2021)

Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes
por: Chou, Ya-Shuan, et al.
Publicado: (2020)

Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy
por: Ho, Yu-Chieh, et al.
Publicado: (2021)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
por: Tokudome, Nahomi, et al.
Publicado: (2020)

Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
por: Brückl, Wolfgang M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ti42po6boocqhhi8fqqqko2amd